Company: BIAF
Filing Date: 2025-09-18
Form Type: 424B3
Source: 0001493152-25-014066
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-18
Form: 424B3
Chunk 3
---
 securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted.

<div align='center'>The date of this prospectus is September 16, 2025</div>

<div align='center'>TABLE OF CONTENTS</div>

|                                                      | Page |
| ABOUT THIS PROSPECTUS                                |   ii |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |  iii |
| PROSPECTUS SUMMARY                                   |    1 |
| THE OFFERING                                         |    6 |
| RISK FACTORS                                         |    7 |
| THE PRIVATE PLACEMENTS                               |    9 |
| SELLING STOCKHOLDERS                                 |   12 |
| DESCRIPTION OF SECURITIES                            |   15 |
| PLAN OF DISTRIBUTION                                 |   20 |
| EXPERTS                                              |   21 |
| LEGAL MATTERS                                        |   21 |
| WHERE YOU CAN FIND ADDITIONAL INFORMATION            |   21 |
| INCORPORATION OF CERTAIN INFORMATION BY REFERENCE    |   22 |

The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the Common Stock offered under this prospectus. The registration statement, including the exhibits, can be read on our website and the website of the Securities and Exchange Commission. See “Where You Can Find Additional Information.”

Information contained in, and that can be accessed through our web site, www.bioaffinity.com,shall not be deemed to be part of this prospectus or incorporated herein by reference and should not be relied upon by any prospective investors for the purposes of determining whether to purchase the Common Stock offered hereunder.

Unless the context otherwise requires, the terms ““we,” “us,” “our,” “the Company,” “bioAffinity” and “our business” refer to bioAffinity Technologies, Inc. and “this offering” refers to the offering contemplated in this prospectus.

| i |

<div align='center'>ABOUT THIS PROSPECTUS</div>

Neither we nor the Selling Stockholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the Selling Stockholders